⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 4, 2026

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

J L Bennett Shamik Bhattacharyya Aram Zabeti M Levy J de Sèze M J Taney Becky Parks K Allen U Akpoji S J Pittock

View Full Paper

Ask AI

Bookmark

Share

Key Points

The analysis aims to assess the safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab.
Post hoc analysis of the CHAMPION-NMOSD trial data
Focused on patients treated with rituximab before ravulizumab
Evaluation of clinical outcomes related to safety and efficacy
Ravulizumab demonstrated a favorable safety profile in treated patients.
Efficacy metrics indicated improvements in clinical outcomes.
No significant adverse events linked to ravulizumab were reported.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Post hoc analysis evaluates safety and efficacy of ravulizumab in NMOSD patients after rituximab therapy, indicating promising outcomes.

Abstract

The CHAMPION-NMOSD Trial; ClinicalTrials.gov identifier: NCT04201262 (registered October 06, 2020).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bennett et al. (2026) studied this question.

synapsesocial.com/papers/69abc2255af8044f7a4eb858 https://doi.org/10.1177/13524585261425076

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)Human Clinical Trial · 2026
2P.011 Efficacy and safety of ravulizumab in adults with AQP4+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial2024
3Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)2024 · 1 citations
4Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum DisorderLate-Phase Clinical Trial · 2026
5A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis (P3-1.006)Original Research · 2026